Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Angina Is as Subjective as Any Other Pain

Almost 80% of all patients randomized in this study reported Canadian Cardiovascular Society class II or III angina, and almost all of them (97%) had more than 1 positive non-invasive ischemia test that matched the area of their single diseased coronary vessel. Beyond fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), the study randomized patients to undergo angioplasty or a sham procedure (placebo group). We might have expected angioplasty patients to resolve their symptoms and placebo patients to continue with the same angina functional class. It should be noted that all patients were symptomatic and they all had single-vessel disease, with ischemia shown in more than one functional study.

Our expectations turned out to be quite different from reality, since almost half the patients who underwent angioplasty continued with angina and, more interestingly, 31.5% of placebo patients (i.e., those who underwent a sham procedure) reported being symptom-free. That is a significant difference, which leads us to conclude that, while angioplasty does actually improve symptoms, some things we are yet to understand.

 

Before randomization, all patients were assessed with iFR and FFR, while results were blinded. Mean FFR was 0.69 ± 0.16 and mean iFR was 0.76±0.22 (undoubtedly, all subjects were ischemic patients) in 196 study patients, among whom 103 underwent angioplasty and 93 underwent a placebo procedure.


Read also: CTO Revascularization Improves Quality of Life.


Angioplasty clearly improved stress echocardiography scores (p < 0.0001) and its effect was progressively more evident with decreasing FFR and iFR (p for interaction < 0.00001). That is the expectable, logical result for this study.

 

However, angioplasty did not improve angina frequency scores significantly more than placebo, and there was no detectable evidence of interaction with FFR (p = 0.849) or iFR (p = 0.783) results.


Read also: Manual vs. Mechanical Compression after Transradial Catheterization.


Despite all of the above, as it was mentioned at the beginning of this article, angioplasty was associated with more freedom from angina (49.5% versus 31.5%; odds ratio [OR]: 2.47; 95% confidence interval [CI]: 1.30 to 4.72; p = 0.006), although neither FFR nor iFR could predict this effect.

 

This is undoubtedly one of the most interesting studies ever published on ischemic heart disease and, despite its scarce 196 patients, it is certainly bound to start a debate.

 

Original title: Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Physiology-Stratified Analysis of ORBITA.

Reference: Al-Lamee R et al. Circulation. 2018 May 22. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...